MedPath

Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

Phase 4
Conditions
Actinic Keratoses
Interventions
Procedure: Cryotherapy
Registration Number
NCT06461442
Lead Sponsor
University of California, Davis
Brief Summary

The goal of this clinical trial is to compare the effectiveness and safety of two treatments-cryotherapy and 5-Fluorouracil (5-FU)-for actinic keratosis, a common skin condition caused by long-term sun exposure. Cryotherapy is a treatment that uses extreme cold produced by liquid nitrogen to freeze and destroy abnormal cells, and 5-FU is a topical cream applied to the skin to treat lesions by interfering with cell growth. The main questions this trial aims to answer are:

* Which treatment, cryotherapy or 5-FU, is more effective in reducing the number of actinic keratosis lesions?

* What are the side effects associated with each treatment?

* How do these treatments impact patient satisfaction, cosmetic outcomes, and health-related quality of life?

Participants will:

* Undergo a baseline assessment where their demographics information such as age, sex, race, smoking status, and medical history are recorded, along with the number and severity of actinic keratosis lesions.

* Receive both cryotherapy and 5-FU, with each treatment applied to different areas of their body. The area of the body to receive each treatment is decided by a random process (like flipping a coin).

* Complete weekly surveys to monitor for side effects during and after the treatment period.

* Return to the clinic for follow-up assessments at 3 months and 12 months.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
73
Inclusion Criteria
  • 18 years of age or older
  • Has a clinical diagnosis of 10 or more AKs in the head, neck, or extremities areas
  • Able to give informed consent themselves
  • Willing to return for follow up visits
Exclusion Criteria
  • Cognitively Impaired
  • Incarcerated
  • Non-English speakers
  • Immuno-comprised status
  • Received any kind of treatment for AK within the past 2 months
  • Use of systemic retinoids within the past 3 months
  • Suspicion of cancer in the target area
  • Porphyria
  • Genetic skin cancer disorders
  • Allergy to trial drugs or peanut/soy products
  • Pregnancy or breast-feeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cryotherapy and 5-Fluoruracil5FluorouracilEach actinic keratosis lesion, or treatment area, will be randomly assigned to receive either cryotherapy or 5-fluoruracil treatment.
Cryotherapy and 5-FluoruracilCryotherapyEach actinic keratosis lesion, or treatment area, will be randomly assigned to receive either cryotherapy or 5-fluoruracil treatment.
Primary Outcome Measures
NameTimeMethod
Partial clearance rate3 months and 12 months

Proportion of patients with at least a 75% reduction in the number of baseline AK lesions within the selected treatment area

Secondary Outcome Measures
NameTimeMethod
Recurrence rate3 months and 12 months

Proportion of participants with recurrent or new lesions within the treatment area

Health-Related Quality of Life3 months and 12 months

Skindex-29 questionnaire

Patient satisfaction3 months and 12 months

Proportion of patients who would choose the same treatment again and if they would recommend it to others

Cosmetic outcome3 months and 12 months

The cosmetic outcome will be evaluated using a 4-point scale (1 = excellent, 2 = good, 3 = moderate, and 4 = poor) by an investigator who is blinded to the treatment allocation

Complete clearance rate3 months and 12 months

Proportion of patients with no clinically visible AK lesions (i.e., a 100% reduction in the number of baseline AK lesions) within the selected treatment area

Percent reduction of AK lesions3 months and 12 months

Decrease in number AK lesions from baseline within the selected treatment area

Rate of progression to keratinocyte carcinoma3 months and 12 months

Proportion of AK lesions within the treatment area that progress to keratinocyte carcinoma

Trial Locations

Locations (1)

University of California, Davis - Dermatology Department

🇺🇸

Sacramento, California, United States

© Copyright 2025. All Rights Reserved by MedPath